Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology · Houston, TX
NPI
1881895993
Since 2007
Specialty
Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology
Code 2084N0402X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
6410 Fannin St, 1010
Houston, TX, 77030
Phone (832) 325-7111
Groups this clinician bills Medicare through
Medicare paid, 2024
$4,261
75 services
Medicare patients, 2024
19
Average age 47
Drug cost, 2024
$414K
307 prescriptions
Company payments, 2025
$33K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mary Kay Koenig was code G2212 (prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or), 50 times for 17 patients. In total Mary Kay Koenig billed 75 services in 5 codes, and Medicare paid $4,261.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-03-27.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 50 | 17 | $25.93 | $1,296 |
| 99215 Office E&M - Established | Office | 21 | 17 | $129.76 | $2,725 |
By year: 2022 $3,886 for 80 services; 2023 $3,760 for 55 services; 2024 $4,261 for 75 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mary Kay Koenig prescribed most often to Medicare patients was Levetiracetam, with 54 prescriptions and refills. In total Mary Kay Koenig wrote 307 Medicare prescriptions that cost $414K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levetiracetam Generic | 54 | 80 | Under 11 | $3,049 |
| Clobazam Generic | 34 | 34 | Under 11 | $3,099 |
| Sertraline Hcl Generic | 31 | 43 | Under 11 | $46.58 |
| Oxcarbazepine Generic | 18 | 18 | Under 11 | $3,839 |
| Clonazepam Generic | 14 | 14 | Under 11 | $96.59 |
| Everolimus Generic | 13 | 13 | Under 11 | $21K |
| Guanfacine Hcl Er Guanfacine Hcl | 12 | 12 | Under 11 | $245 |
| Lamictal Lamotrigine | 12 | 12 | Under 11 | $9,137 |
| Carbamazepine Er Carbamazepine | 12 | 12 | Under 11 | $1,179 |
| Trileptal Oxcarbazepine | 12 | 12 | Under 11 | $23K |
| Vigabatrin Generic | 12 | 12 | Under 11 | $312K |
| Zonisamide Generic | 12 | 12 | Under 11 | $376 |
Brand drugs: 41 claims; generic drugs: 266 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mary Kay Koenig $33K ($33K in general payments such as food, travel and fees) from 10 companies. The largest payer was Jazz Pharmaceuticals Inc. with $30K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.